Chongqing Precision Biotech Co., Ltd. was established in 2016 as a high-tech enterprise jointly established by a technical team with Professor Qian Cheng as the leader, a well-known scientist of precision medicine, and listed company, Zhifei Bio (Zhirui Investment). The company takes gene editing and synthetic Biotechtechnology as the breakthrough point, mainly engaged in the development and application of gene and cell medicine, and has become the leading enterprise in the field of CAR-T/NK in China. We determined to become a global, innovative and pioneering biopharmaceutical enterprise.

Adhering to the core concept of "keep improving and be meticulous", we focus on scientific research and continuously innovates. We have established R&D cooperation and expert exchange mechanisms with many overseas institutes and domestic universities, bringing together many experts and scholars and over 100 R&D elite team members. We set up an industrial technology research institute and a postdoctoral workstation, and have been approved as a new high-end research and development institution, key laboratory, engineering research center and other platform construction units in Chongqing.

As a scientific and technological innovation enterprise, the company grasps the key technologies in the field of cells, has a number of authorized invention patents and laid out patents in developed countries and regions. We has implemented and promoted more than 10 CAR-T R&D pipelines for leukemia, lymphoma, myeloma, gastrointestinal cancer, lung cancer, liver cancer, breast cancer and pancreatic cancer, and obtained implied licenses for four Class I CAR-T cell biological new drugs and ten indications. The first domestic self-developed pCAR-19B cell autologous infusion preparation for the treatment of childhood leukemia has been approved as "Breakthrough Therapy Designation" and included in the priority review. In 2024, NMPA has accepted our New Drug Application for pCAR-19B. Meanwhile, we has achieved technical breakthroughs in the treatment of renal cancer, colorectal cancer, gastric cancer and other solid tumors with CAR-T, and relevant products have been approved for clinical registration and are actively promoting clinical drug registration.

We have built an upstream and downstream integrated platform of 18,000-square-meter covering the development of cellular drugs, which can support the pre-clinical research, technological research and development, analytical testing and technological production of drugs IND and NDA. We are the first gene and cell pharmaceutical enterprise in western China and one of the few in China that has been granted CAR-T Pharmaceutical Production License. At the same time, we plans to build a regional cell preparation center in West Science City of Chongqing , covering an area of about 154 mu, with a planned total investment of 3 billion yuan.

We will continue to adhere to our mission of "innovation for health", make innovations for cell therapy technology and focus on malignant tumor treatment. Based on the domestic and international dual-cycle strategy, we will implement the strategy of globalization of technical resources and internationalization of marketing, build a regional cell preparation base in China, explore the establishment of overseas R&D branches, and strive to build a biomedical enterprise with global competitiveness.